Literature DB >> 7796606

Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.

L S Engel1, M C Callegan, J A Hobden, J J Reidy, J M Hill, R J O'Callaghan.   

Abstract

Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis. We investigated the therapeutic effectiveness of tobramycin/prednisolone and ciprofloxacin/dexamethasone in a rabbit model of experimental keratitis to increase our understanding of the effectiveness of antibiotic/steroid combinations. To our knowledge, this is the first analysis of the effectiveness of a combination of ciprofloxacin and dexamethasone for experimental keratitis. Two experiments were conducted. In the first experiment, 36 rabbits were divided into six groups: 1) untreated; 2) prednisolone acetate, 1.0%; 3) prednisolone phosphate, 1.0%; 4) tobramycin, 1.36%; 5) tobramycin plus prednisolone acetate; 6) tobramycin plus prednisolone phosphate. In the second experiment, 23 rabbits were divided into four groups: 1) untreated; 2) ciprofloxacin, 0.3%, plus dexamethasone alcohol, 0.1%; 3) ciprofloxacin; 4) dexamethasone alcohol. Topical antibiotic and/or steroid was given for 10 h, from 16 to 26 h postinfection, one drop every 15 min for the first hour and then every 30 min for the remaining 9 h. At 27 h postinfection, eyes were evaluated by slit lamp examination (SLE) and assayed for the presence of bacteria in terms of colony forming units (CFU) per cornea. Both prednisolone acetate and prednisolone phosphate reduced ocular inflammation (as determined by SLE), compared with no treatment (P < or = 0.036); the phosphate was more effective (P = 0.005). Tobramycin alone and in combination with prednisolone also significantly reduced SLE, compared with no treatment (P < or = 0.006). The bactericidal activity of tobramycin was not affected by either steroid formulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796606     DOI: 10.3109/02713689509033519

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  15 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  The steroids for corneal ulcers trial: study design and baseline characteristics.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

3.  Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

4.  Vincamine prevents lipopolysaccharide induced inflammation and oxidative stress via thioredoxin reductase activation in human corneal epithelial cells.

Authors:  Li Wu; Meihong Ye; Jie Zhang
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

5.  Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.

Authors:  Aileen Sy; Muthiah Srinivasan; Jeena Mascarenhas; Prajna Lalitha; Revathi Rajaraman; Meenakshi Ravindran; Catherine E Oldenburg; Kathryn J Ray; David Glidden; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

6.  The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; Kieran S O'Brien; David V Glidden; Kathryn J Ray; Catherine E Oldenburg; Michael E Zegans; John P Whitcher; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2013-10-01       Impact factor: 5.258

7.  TREM-1 amplifies corneal inflammation after Pseudomonas aeruginosa infection by modulating Toll-like receptor signaling and Th1/Th2-type immune responses.

Authors:  Minhao Wu; Anping Peng; Mingxia Sun; Qiuchan Deng; Linda D Hazlett; Jin Yuan; Xialin Liu; Qianying Gao; Lianqiang Feng; Junfang He; Ping Zhang; Xi Huang
Journal:  Infect Immun       Date:  2011-05-09       Impact factor: 3.441

8.  TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway.

Authors:  Mingxia Sun; Min Zhu; Kang Chen; Xinxin Nie; Qiuchan Deng; Linda D Hazlett; Yongjian Wu; Meiyu Li; Minhao Wu; Xi Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-17       Impact factor: 4.799

9.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

10.  Nocardia keratitis: clinical course and effect of corticosteroids.

Authors:  Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Jeganathan Lakshmi Priya; Aileen Sy; Catherine E Oldenburg; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2012-09-05       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.